Immunohistochemical	O
staining	O
was	O
positive	O
for	O
S	B-GENE
-	I-GENE
100	I-GENE
in	O
all	O
9	O
cases	O
stained	O
,	O
positive	O
for	O
HMB	B-GENE
-	I-GENE
45	I-GENE
in	O
9	O
(	O
90	O
%	O
)	O
of	O
10	O
,	O
and	O
negative	O
for	O
cytokeratin	B-GENE
in	O
all	O
9	O
cases	O
in	O
which	O
myxoid	O
melanoma	O
remained	O
in	O
the	O
block	O
after	O
previous	O
sections	O
.	O

Chloramphenicol	B-GENE
acetyltransferase	I-GENE
assays	O
examining	O
the	O
ability	O
of	O
IE86	B-GENE
to	O
repress	O
activity	O
from	O
the	O
HCMV	O
major	O
IE	B-GENE
promoter	I-GENE
or	O
activate	O
the	O
HCMV	B-GENE
early	I-GENE
promoter	I-GENE
for	O
the	O
2	O
.	O
2	O
-	O
kb	O
class	O
of	O
RNAs	O
demonstrated	O
the	O
functional	O
integrity	O
of	O
the	O
IE86	B-GENE
protein	I-GENE
.	O

A	O
new	O
DNA	B-GENE
repair	I-GENE
gene	I-GENE
from	O
Schizosaccharomyces	O
pombe	O
with	O
homology	O
to	O
RecA	B-GENE
was	O
identified	O
and	O
characterized	O
.	O

Our	O
study	O
also	O
demonstrated	O
significant	O
increases	O
in	O
the	O
number	O
of	O
larger	O
myelinated	O
fibers	O
crossing	O
the	O
repair	O
site	O
in	O
comparison	O
with	O
the	O
neonatal	O
and	O
adult	O
groups	O
(	O
p	O
<	O
0	O
.	O
04	O
)	O
.	O

Cloning	O
and	O
sequencing	O
of	O
the	O
upstream	O
region	O
of	O
pepX	B-GENE
revealed	O
the	O
presence	O
of	O
two	O
ORFs	O
of	O
360	O
and	O
1	O
,	O
338	O
bp	O
that	O
were	O
shown	O
to	O
be	O
able	O
to	O
encode	O
proteins	O
with	O
high	O
homology	O
to	O
GlnR	B-GENE
and	O
GlnA	B-GENE
proteins	I-GENE
,	O
respectively	O
.	O

Both	O
mutant	O
receptors	O
were	O
expressed	O
on	O
the	O
cell	O
surface	O
and	O
bound	O
insulin	B-GENE
normally	O
,	O
but	O
showed	O
markedly	O
impaired	O
autophosphorylation	O
in	O
response	O
to	O
insulin	B-GENE
.	O

Furthermore	O
,	O
analysis	O
of	O
the	O
E2	B-GENE
proteins	I-GENE
present	O
in	O
various	O
cell	O
lines	O
harboring	O
specific	O
BPV	O
-	O
1	O
mutants	O
,	O
including	O
the	O
2558	O
acceptor	O
mutant	O
,	O
proves	O
that	O
alternate	O
modes	O
of	O
E2	B-GENE
expression	O
exist	O
.	O

Molecular	O
modelling	O
suggested	O
that	O
the	O
tetramerization	O
domain	O
was	O
a	O
four	O
-	O
helix	O
bundle	O
,	O
stabilized	O
by	O
interactions	O
of	O
seven	O
conserved	O
aromatic	O
amino	O
acids	O
.	O

Hematology	O
problem	O
of	O
the	O
month	O
:	O
band	O
or	O
seg	O
?	O

PKA	B-GENE
phosphorylated	O
WT1	B-GENE
at	O
Ser	O
-	O
365	O
and	O
Ser	O
-	O
393	O
in	O
vitro	O
,	O
as	O
well	O
as	O
at	O
additional	O
sites	O
,	O
and	O
this	O
phosphorylation	O
abolished	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
WT1	B-GENE
in	O
vitro	O
.	O

ROCK	B-GENE
-	I-GENE
I	I-GENE
,	O
Kinectin	B-GENE
,	O
and	O
mDia2	B-GENE
can	O
bind	O
the	O
wild	O
type	O
forms	O
of	O
both	O
RhoA	B-GENE
and	O
Cdc42	B-GENE
in	O
a	O
GTP	O
-	O
dependent	O
manner	O
in	O
vitro	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
in	O
the	O
presence	O
of	O
tryptophan	O
the	O
ribosome	O
translating	O
tnaC	B-GENE
blocks	O
Rho	B-GENE
'	O
s	O
access	O
to	O
the	O
boxA	B-GENE
and	O
rut	B-GENE
sites	I-GENE
,	O
thereby	O
preventing	O
transcription	O
termination	O
.	O

Suppressors	O
of	O
defective	O
silencing	O
in	O
yeast	O
:	O
effects	O
on	O
transcriptional	O
repression	O
at	O
the	O
HMR	B-GENE
locus	I-GENE
,	O
cell	O
growth	O
and	O
telomere	O
structure	O
.	O

The	O
pJR	O
vectors	O
differ	O
among	O
them	O
in	O
:	O
(	O
a	O
)	O
the	O
selectable	O
marker	O
(	O
Saccharomyces	O
cerevisiae	O
LEU	B-GENE
2	I-GENE
gene	I-GENE
,	O
which	O
complements	O
S	B-GENE
.	I-GENE
pombe	I-GENE
leu1	I-GENE
-	I-GENE
gene	I-GENE
and	O
S	O
.	O
pombe	O
ura4	B-GENE
+	I-GENE
and	O
his3	B-GENE
+	I-GENE
genes	I-GENE
)	O
;	O
(	O
b	O
)	O
the	O
thiamine	O
-	O
repressible	O
nmt1	B-GENE
promoter	I-GENE
(	O
3X	O
,	O
41X	O
and	O
81X	O
with	O
extremely	O
high	O
,	O
moderate	O
or	O
low	O
transcription	O
efficiency	O
,	O
respectively	O
)	O
;	O
and	O
(	O
c	O
)	O
the	O
multiple	O
cloning	O
site	O
(	O
two	O
multiple	O
cloning	O
sites	O
,	O
with	O
12	O
restriction	O
sites	O
each	O
)	O
.	O

DPP6	O
as	O
a	O
candidate	O
gene	O
for	O
neuroleptic	O
-	O
induced	O
tardive	O
dyskinesia	O
.	O

We	O
implemented	O
a	O
two	O
-	O
step	O
approach	O
to	O
detect	O
potential	O
predictor	O
gene	O
variants	O
for	O
neuroleptic	O
-	O
induced	O
tardive	O
dyskinesia	O
(	O
TD	O
)	O
in	O
schizophrenic	O
subjects	O
.	O

First	O
,	O
we	O
screened	O
associations	O
by	O
using	O
a	O
genome	O
-	O
wide	O
(	O
Illumina	O
HumanHapCNV370	O
)	O
SNP	O
array	O
in	O
61	O
Japanese	O
schizophrenia	O
patients	O
with	O
treatment	O
-	O
resistant	O
TD	O
and	O
61	O
Japanese	O
schizophrenia	O
patients	O
without	O
TD	O
.	O

Next	O
,	O
we	O
performed	O
a	O
replication	O
analysis	O
in	O
36	O
treatment	O
-	O
resistant	O
TD	O
and	O
138	O
non	O
-	O
TD	O
subjects	O
.	O

An	O
association	O
of	O
an	O
SNP	O
in	O
the	O
DPP6	O
(	O
dipeptidyl	O
peptidase	O
-	O
like	O
protein	O
-	O
6	O
)	O
gene	O
,	O
rs6977820	O
,	O
the	O
most	O
promising	O
association	O
identified	O
by	O
the	O
screen	O
,	O
was	O
significant	O
in	O
the	O
replication	O
sample	O
(	O
allelic	O
P	O
=	O
0	O
.	O
008	O
in	O
the	O
replication	O
sample	O
,	O
allelic	O
P	O
=	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
6	O
)	O
,	O
odds	O
ratio	O
2	O
.	O
32	O
in	O
the	O
combined	O
sample	O
)	O
.	O

The	O
SNP	O
is	O
located	O
in	O
intron	O
-	O
1	O
of	O
the	O
DPP6	O
gene	O
and	O
the	O
risk	O
allele	O
was	O
associated	O
with	O
decreased	O
DPP6	O
gene	O
expression	O
in	O
the	O
human	O
postmortem	O
prefrontal	O
cortex	O
.	O

Chronic	O
administration	O
of	O
haloperidol	B-Chemical
increased	O
Dpp6	O
expression	O
in	O
mouse	O
brains	O
.	O

DPP6	O
is	O
an	O
auxiliary	O
subunit	O
of	O
Kv4	O
and	O
regulates	O
the	O
properties	O
of	O
Kv4	O
,	O
which	O
regulates	O
the	O
activity	O
of	O
dopaminergic	O
neurons	O
.	O

The	O
findings	O
of	O
this	O
study	O
indicate	O
that	O
an	O
altered	O
response	O
of	O
Kv4	O
/	O
DPP6	O
to	O
long	O
-	O
term	O
neuroleptic	O
administration	O
is	O
involved	O
in	O
neuroleptic	O
-	O
induced	O
TD	O
.	O

Nanosilver	O
effects	O
on	O
growth	O
parameters	O
in	O
experimental	O
aflatoxicosis	O
in	O
broiler	O
chickens	O
.	O

Aflatoxicosis	O
is	O
a	O
cause	O
of	O
economic	O
losses	O
in	O
broiler	O
production	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
one	O
commercial	O
nanocompound	O
,	O
Nanocid	O
(	O
Nano	O
Nasb	O
Pars	O
Co	O
.	O
,	O
Iran	O
)	O
was	O
evaluated	O
in	O
reduction	O
of	O
aflatoxin	B-Chemical
effects	O
on	O
the	O
growth	O
and	O
performance	O
indices	O
in	O
broiler	O
chickens	O
suffering	O
from	O
experimental	O
aflatoxicosis	O
.	O

For	O
this	O
,	O
a	O
total	O
of	O
300	O
one	O
-	O
day	O
-	O
old	O
broiler	O
chicks	O
(	O
Ross	O
strain	O
)	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
with	O
3	O
replicates	O
of	O
15	O
chicks	O
in	O
each	O
separated	O
pen	O
during	O
the	O
28	O
-	O
day	O
experiment	O
.	O

Treatment	O
groups	O
including	O
group	O
A	O
:	O
chickens	O
fed	O
basal	O
diet	O
,	O
group	O
B	O
:	O
chickens	O
fed	O
3	O
ppm	O
productive	O
aflatoxin	B-Chemical
in	O
basal	O
diet	O
,	O
group	O
C	O
:	O
chickens	O
fed	O
basal	O
diet	O
plus	O
2500	O
ppm	O
Nanocid	O
,	O
and	O
group	O
D	O
:	O
chickens	O
fed	O
3	O
ppm	O
productive	O
aflatoxin	B-Chemical
and	O
2500	O
ppm	O
Nanocid	O
,	O
in	O
basal	O
diet	O
.	O

Data	O
on	O
body	O
weight	O
,	O
body	O
weight	O
gain	O
(	O
BWG	O
)	O
,	O
feed	O
intake	O
,	O
and	O
feed	O
conversion	O
ratio	O
(	O
FCR	O
)	O
were	O
recorded	O
at	O
weekly	O
intervals	O
.	O

Also	O
cumulative	O
data	O
were	O
assessed	O
.	O

Results	O
showed	O
,	O
although	O
supplement	O
of	O
Nanocid	O
to	O
conventional	O
diet	O
had	O
no	O
effect	O
on	O
performance	O
but	O
addition	O
of	O
Nanocid	O
to	O
diet	O
containing	O
3	O
ppm	O
aflatoxin	B-Chemical
increased	O
significantly	O
the	O
cumulative	O
BWG	O
,	O
cumulative	O
feed	O
consumption	O
and	O
decreased	O
FCR	O
in	O
the	O
last	O
2	O
weeks	O
of	O
experimental	O
period	O
.	O

The	O
improvement	O
in	O
these	O
performance	O
indices	O
by	O
supplement	O
of	O
Nanocid	O
to	O
diet	O
containing	O
aflatoxin	B-Chemical
showed	O
the	O
ability	O
of	O
Nanocid	O
to	O
diminish	O
the	O
inhibitory	O
effects	O
of	O
aflatoxin	B-Chemical
.	O

The	O
influence	O
of	O
the	O
intensity	O
of	O
smoking	O
and	O
years	O
of	O
work	O
in	O
the	O
metallurgy	O
on	O
pro	O
-	O
oxidant	O
/	O
antioxidant	O
balance	O
in	O
the	O
blood	O
of	O
smelters	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
cigarette	O
smoking	O
and	O
occupational	O
exposure	O
to	O
heavy	O
metals	O
on	O
the	O
degree	O
of	O
pro	O
-	O
oxidant	O
/	O
antioxidant	O
imbalance	O
in	O
smelters	O
.	O

The	O
investigations	O
were	O
performed	O
on	O
the	O
blood	O
and	O
urine	O
of	O
400	O
subjects	O
:	O
300	O
male	O
copper	B-Chemical
smelters	O
and	O
100	O
nonexposed	O
male	O
subjects	O
.	O

Selegiline	B-Chemical
-	O
induced	O
postural	B-Disease
hypotension	I-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
a	O
longitudinal	O
study	O
on	O
the	O
effects	O
of	O
drug	O
withdrawal	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
10	O
mg	O
selegiline	B-Chemical
per	O
day	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
compared	O
with	O
those	O
taking	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
alone	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
was	O
associated	O
with	O
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
abolished	O
by	O
withdrawal	O
of	O
selegiline	B-Chemical
.	O

This	O
unwanted	O
effect	O
on	O
postural	O
blood	O
pressure	O
was	O
not	O
the	O
result	O
of	O
underlying	O
autonomic	O
failure	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
confirm	O
our	O
previous	O
findings	O
in	O
a	O
separate	O
cohort	O
of	O
patients	O
and	O
to	O
determine	O
the	O
time	O
course	O
of	O
the	O
cardiovascular	O
consequences	O
of	O
stopping	O
selegiline	B-Chemical
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	O
on	O
the	O
mechanisms	O
by	O
which	O
the	O
drug	O
causes	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	B-Disease
patients	O
receiving	O
selegiline	B-Chemical
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

RESULTS	O
:	O
Head	O
-	O
up	O
tilt	O
caused	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-Disease
patients	O
on	O
selegiline	B-Chemical
,	O
one	O
of	O
whom	O
lost	O
consciousness	O
with	O
unrecordable	O
blood	O
pressures	O
.	O

A	O
lesser	O
degree	O
of	O
orthostatic	B-Disease
hypotension	I-Disease
occurred	O
with	O
standing	O
.	O

Orthostatic	B-Disease
hypotension	I-Disease
was	O
ameliorated	O
4	O
days	O
after	O
withdrawal	O
of	O
selegiline	B-Chemical
and	O
totally	O
abolished	O
7	O
days	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Stopping	O
selegiline	B-Chemical
also	O
significantly	O
reduced	B-Disease
the	I-Disease
supine	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
blood	I-Disease
pressures	I-Disease
consistent	O
with	O
a	O
previously	O
undescribed	O
supine	O
pressor	O
action	O
.	O

CONCLUSION	O
:	O
This	O
study	O
confirms	O
our	O
previous	O
finding	O
that	O
selegiline	B-Chemical
in	O
combination	O
with	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
is	O
associated	O
with	O
selective	O
orthostatic	B-Disease
hypotension	I-Disease
.	O

The	O
possibilities	O
that	O
these	O
cardiovascular	O
findings	O
might	O
be	O
the	O
result	O
of	O
non	O
-	O
selective	O
inhibition	O
of	O
monoamine	O
oxidase	O
or	O
of	O
amphetamine	B-Chemical
and	O
metamphetamine	B-Chemical
are	O
discussed	O
.	O

Further	O
studies	O
on	O
effects	O
of	O
irrigation	O
solutions	O
on	O
rat	O
bladders	O
.	O

Further	O
studies	O
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	O
bladder	O
for	O
18	O
hours	O
are	O
reported	O
.	O

The	O
results	O
have	O
shown	O
that	O
the	O
degradation	O
product	O
p	B-Chemical
-	I-Chemical
choloroaniline	I-Chemical
is	O
not	O
a	O
significant	O
factor	O
in	O
chlorhexidine	B-Chemical
-	I-Chemical
digluconate	I-Chemical
associated	O
erosive	O
cystitis	B-Disease
.	O

A	O
high	O
percentage	O
of	O
kanamycin	B-Chemical
-	O
colistin	B-Chemical
and	O
povidone	B-Chemical
-	I-Chemical
iodine	I-Chemical
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	B-Disease
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

Picloxydine	B-Chemical
irrigations	O
appeared	O
to	O
have	O
a	O
lower	O
incidence	O
of	O
erosive	O
cystitis	B-Disease
but	O
further	O
studies	O
would	O
have	O
to	O
be	O
performed	O
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	O
.	O

IL-2	B-DNA
gene	I-DNA
expression	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
CD28	B-protein
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B-protein
.	O

Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
we	O
show	O
that	O
CD28	B-protein
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-protein
-mediated	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
/	O
CD28-responsive	B-protein
complex	I-protein
and	O
IL-2	B-protein
expression	O
.	O

Delineation	O
of	O
the	O
CD28	B-protein
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	B-protein
metabolites	I-protein
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B-protein
expression	O
via	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

The	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
mediates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
enhancer	I-DNA
activation	O
in	O
monocytes	B-cell_type
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	B-DNA
element	I-DNA
within	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
,	O
immediately	O
upstream	O
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
designated	O
peri-kappa	B-DNA
B	I-DNA
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	B-DNA
enhancer	I-DNA
activation	O
following	O
stimulation	O
of	O
monocytic	B-cell_line
but	O
not	O
T-cell	B-cell_line
lines	I-cell_line
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B-DNA
element	I-DNA
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O

While	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
binds	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	B-cell_type
versus	O
T	B-cell_type
cells	I-cell_type
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	B-DNA
element	I-DNA
undergoes	O
differential	O
modification	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
seen	O
in	O
monocytes	B-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Scp160p	O
,	O
a	O
multiple	O
KH	O
-	O
domain	O
protein	O
,	O
is	O
a	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	B-Species
.	O

Scp160p	O
is	O
a	O
160	O
kDa	O
protein	O
in	O
the	O
yeast	B-Species
Saccharomyces	B-Species
cerevisiae	I-Species
that	O
contains	O
14	O
repeats	O
of	O
the	O
hnRNP	O
K	O
-	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
and	O
demonstrates	O
significant	O
sequence	O
homology	O
to	O
a	O
family	O
of	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

As	O
a	O
first	O
step	O
towards	O
defining	O
the	O
function	O
of	O
Scp160p	O
,	O
we	O
have	O
characterized	O
the	O
subcellular	O
distribution	O
and	O
in	O
vivo	O
interactions	O
of	O
this	O
protein	O
.	O

Using	O
sucrose	O
gradient	O
fractionation	O
studies	O
we	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
predominantly	O
associated	O
with	O
polyribosomes	O
.	O

Furthermore	O
,	O
we	O
have	O
found	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
by	O
EDTA	O
in	O
the	O
form	O
of	O
a	O
large	O
complex	O
of	O
>=	O
1300	O
kDa	O
that	O
is	O
sensitive	O
both	O
to	O
RNase	O
and	O
NaCl	O
.	O

Using	O
affinity	O
-	O
chromatography	O
to	O
isolate	O
these	O
complexes	O
,	O
we	O
have	O
identified	O
two	O
protein	O
components	O
other	O
than	O
Scp160p	O
:	O
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
confirms	O
these	O
complexes	O
to	O
be	O
mRNPs	O
.	O

The	O
presence	O
of	O
Bfr1p	O
is	O
intriguing	O
because	O
the	O
null	O
phenotype	O
for	O
this	O
gene	O
is	O
essentially	O
the	O
same	O
as	O
that	O
reported	O
for	O
scp160	O
-	O
null	O
cells	O
:	O
increased	O
cell	O
size	O
and	O
aberrant	O
DNA	O
content	O
.	O

These	O
results	O
demonstrate	O
that	O
Scp160p	O
associates	O
with	O
polyribosome	O
-	O
bound	O
mRNP	O
complexes	O
in	O
vivo	O
,	O
implicating	O
a	O
role	O
for	O
this	O
protein	O
in	O
one	O
or	O
more	O
levels	O
of	O
mRNA	O
metabolism	O
in	O
yeast	B-Species
.	O

INTRODUCTION	O

Scp160p	O
is	O
a	O
1222	O
amino	O
acid	O
Saccharomyces	B-Species
cerevisiae	I-Species
protein	O
that	O
contains	O
14	O
copies	O
of	O
the	O
hnRNP	O
K	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
a	O
highly	O
conserved	O
motif	O
found	O
in	O
many	O
proteins	O
involved	O
in	O
RNA	O
metabolism	O
(	O
1	O
)	O
.	O

KH	O
domain	O
-	O
containing	O
proteins	O
appear	O
to	O
have	O
diverse	O
functions	O
and	O
have	O
been	O
identified	O
in	O
all	O
kingdoms	O
of	O
life	O
,	O
including	O
the	O
ribosomal	O
protein	O
S3	O
from	O
Escherichia	B-Species
coli	I-Species
(	O
1	O
)	O
,	O
Mer1p	O
from	O
S	B-Species
.	I-Species
cerevisiae	I-Species
,	O
a	O
meiosis	O
-	O
specific	O
splicing	O
factor	O
(	O
1	O
)	O
,	O
MEX	O
-	O
3	O
from	O
Caenorhabditis	B-Species
elegans	I-Species
,	O
presumably	O
involved	O
in	O
mRNA	O
localization	O
during	O
development	O
(	O
2	O
)	O
,	O
and	O
FMRP	O
,	O
the	O
fragile	O
-	O
X	O
mental	O
retardation	O
protein	O
in	O
humans	B-Species
(	O
3	O
)	O
.	O

A	O
partial	O
clone	O
of	O
Scp160p	O
,	O
known	O
as	O
HX	O
,	O
was	O
one	O
of	O
the	O
first	O
multiple	O
-	O
KH	O
proteins	O
identified	O
(	O
1	O
)	O
.	O

Whole	O
cell	O
immunofluorescence	O
studies	O
have	O
demonstrated	O
that	O
Scp160p	O
localizes	O
to	O
the	O
cytoplasm	O
,	O
with	O
enrichment	O
around	O
the	O
nuclear	O
envelope	O
,	O
and	O
what	O
appears	O
to	O
be	O
the	O
endoplasmic	O
reticulum	O
(	O
3	O
)	O
.	O

Deletion	O
of	O
the	O
SCP160	O
locus	O
in	O
yeast	B-Species
is	O
not	O
lethal	O
,	O
but	O
results	O
in	O
a	O
complex	O
phenotype	O
,	O
including	O
increased	O
DNA	O
content	O
per	O
cell	O
,	O
missegregation	O
of	O
genetic	O
markers	O
during	O
sporulation	O
,	O
and	O
abnormal	O
cell	O
morphology	O
,	O
including	O
increased	O
size	O
and	O
irregular	O
shape	O
(	O
4	O
)	O
.	O

Observation	O
of	O
this	O
phenotype	O
led	O
to	O
the	O
hypothesis	O
that	O
Scp160p	O
may	O
function	O
in	O
regulating	O
ploidy	O
during	O
cell	O
division	O
.	O

More	O
recently	O
,	O
Weber	O
and	O
colleagues	O
demonstrated	O
in	O
vitro	O
RNA	O
binding	O
activity	O
of	O
Scp160p	O
using	O
northwestern	O
blot	O
analyses	O
;	O
the	O
protein	O
was	O
found	O
to	O
bind	O
efficiently	O
to	O
ribohomopolymers	O
and	O
rRNA	O
,	O
but	O
not	O
to	O
tRNA	O
(	O
5	O
)	O
.	O

Identification	O
of	O
APC2	O
,	O
a	O
homologue	O
of	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
tumour	I-Disease
suppressor	O
.	O

The	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	I-Disease
APC	I-Disease
)	I-Disease
tumour	I-Disease
-	O
suppressor	O
protein	O
controls	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
forming	O
a	O
complex	O
with	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
axin	O
/	O
conductin	O
and	O
betacatenin	O
.	O

Complex	O
formation	O
induces	O
the	O
rapid	O
degradation	O
of	O
betacatenin	O
.	O

In	O
colon	B-Disease
carcinoma	I-Disease
cells	O
,	O
loss	O
of	O
APC	O
leads	O
to	O
the	O
accumulation	O
of	O
betacatenin	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
and	O
activates	O
the	O
Tcf	O
-	O
4	O
transcription	O
factor	O
(	O
reviewed	O
in	O
[	O
1	O
]	O
[	O
2	O
]	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
genomic	O
structure	O
of	O
APC	O
homologues	O
.	O

Mammalian	O
APC2	O
,	O
which	O
closely	O
resembles	O
APC	O
in	O
overall	O
domain	O
structure	O
,	O
was	O
functionally	O
analyzed	O
and	O
shown	O
to	O
contain	O
two	O
SAMP	O
domains	O
,	O
both	O
of	O
which	O
are	O
required	O
for	O
binding	O
to	O
conductin	O
.	O

Like	O
APC	O
,	O
APC2	O
regulates	O
the	O
formation	O
of	O
active	O
betacatenin	O
-	O
Tcf	O
complexes	O
,	O
as	O
demonstrated	O
using	O
transient	O
transcriptional	O
activation	O
assays	O
in	O
APC	O
-	O
/	O
-	O
colon	B-Disease
carcinoma	I-Disease
cells	O
.	O

Human	O
APC2	O
maps	O
to	O
chromosome	O
19p13	O
.	O

3	O
.	O

APC	O
and	O
APC2	O
may	O
therefore	O
have	O
comparable	O
functions	O
in	O
development	O
and	O
cancer	B-Disease
.	O

A	O
common	O
MSH2	O
mutation	O
in	O
English	O
and	O
North	O
American	O
HNPCC	B-Disease
families	O
:	O
origin	O
,	O
phenotypic	O
expression	O
,	O
and	O
sex	O
specific	O
differences	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O

The	O
frequency	O
,	O
origin	O
,	O
and	O
phenotypic	O
expression	O
of	O
a	O
germline	O
MSH2	O
gene	O
mutation	O
previously	O
identified	O
in	O
seven	O
kindreds	O
with	O
hereditary	B-Disease
non	I-Disease
-	I-Disease
polyposis	I-Disease
cancer	I-Disease
syndrome	I-Disease
(	O
HNPCC	B-Disease
)	O
was	O
investigated	O
.	O

The	O
mutation	O
(	O
A	O
-	O
-	O
>	O
T	O
at	O
nt943	O
+	O
3	O
)	O
disrupts	O
the	O
3	O
splice	O
site	O
of	O
exon	O
5	O
leading	O
to	O
the	O
deletion	O
of	O
this	O
exon	O
from	O
MSH2	O
mRNA	O
and	O
represents	O
the	O
only	O
frequent	O
MSH2	O
mutation	O
so	O
far	O
reported	O
.	O

Although	O
this	O
mutation	O
was	O
initially	O
detected	O
in	O
four	O
of	O
33	O
colorectal	B-Disease
cancer	I-Disease
families	O
analysed	O
from	O
eastern	O
England	O
,	O
more	O
extensive	O
analysis	O
has	O
reduced	O
the	O
frequency	O
to	O
four	O
of	O
52	O
(	O
8	O
%	O
)	O
English	O
HNPCC	B-Disease
kindreds	O
analysed	O
.	O

In	O
contrast	O
,	O
the	O
MSH2	O
mutation	O
was	O
identified	O
in	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
separately	O
identified	O
colorectal	B-Disease
families	O
from	O
Newfoundland	O
.	O

To	O
investigate	O
the	O
origin	O
of	O
this	O
mutation	O
in	O
colorectal	B-Disease
cancer	I-Disease
families	O
from	O
England	O
(	O
n	O
=	O
4	O
)	O
,	O
Newfoundland	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
n	O
=	O
3	O
)	O
,	O
haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
linked	O
to	O
MSH2	O
was	O
performed	O
.	O

Within	O
the	O
English	O
and	O
US	O
families	O
there	O
was	O
little	O
evidence	O
for	O
a	O
recent	O
common	O
origin	O
of	O
the	O
MSH2	O
splice	O
site	O
mutation	O
in	O
most	O
families	O
.	O

In	O
contrast	O
,	O
a	O
common	O
haplotype	O
was	O
identified	O
at	O
the	O
two	O
flanking	O
markers	O
(	O
CA5	O
and	O
D2S288	O
)	O
in	O
eight	O
of	O
the	O
Newfoundland	O
families	O
.	O

IL-1	B-protein
induces	O
a	O
rapid	O
,	O
protein	O
synthesis-independent	O
appearance	O
of	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B-protein
and	O
IL-12	B-protein
synergized	O
in	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
mRNAs	I-RNA
.	O